BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study

Gynecologic Oncology

Volumn 140, Issue 3, 2016, Pages 443-449

  Harter, Philipp ^a   Johnson, Toby ^b   Berton Rigaud, Dominique ^c   Park, Sang Yoon ^d   Friedlander, Michael ^e   Del Campo, Josep M ^f   Shimada, Muneaki ^g   Forget, Frédéric ^h   Mirza, Mansoor R ⁱ   Colombo, Nicoletta ^j   Zamagni, Claudio ^k   Chan, John K ^l   Imhof, Martin ^m   Herzog, Thomas J ⁿ   O'Donnell, Dearbhaile ^o   Heitz, Florian ^a   King, Karen ^p   Stinnett, Sandy ^p   Barrett, Catherine ^q   Jobanputra, Minesh ^r   Xu, Chun Fang ^b   Du Bois, Andreas ^a   more..

^a KLINIKEN ESSEN MITTE   (Germany)

^b GLAXOSMITHKLINE   (United Kingdom)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d National Cancer Center   (South Korea)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g TOTTORI UNIVERSITY   (Japan)

^h Centre Hospitalier de l'Ardenne   (Belgium)

ⁱ University of Copenhagen   (Denmark)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l California Pacific and Palo Alto Sutter Cancer Research Institute   (United States)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ UNIVERSITY OF CINCINNATI   (United States)

^o All Ireland Cooperative Oncology Research Group   (Ireland)

^p PAREXEL INTERNATIONAL   (United States)

^q NOVARTIS PHARMA AG   (Switzerland)

^r Medical Research   (United Kingdom)

more..

Author keywords

Germline BRCA mutation; GWAS; Ovarian cancer; Pazopanib; Progression free survival

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PAZOPANIB; PLACEBO; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXON; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; UTERINE TUBE CARCINOMA; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TUMOR SUPPRESSOR GENE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; HUMANS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PYRIMIDINES; SULFONAMIDES; YOUNG ADULT;

EID: 84959450892     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.12.027     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts & Figures 2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. (Accessed: February 4, 2015)
2. T. Thigpen, A. duBois, J. McAlpine, P. DiSaia, K. Fujiwara, W. Hoskins, and et al. First-line therapy in ovarian cancer trials Int. J. Gynecol. Cancer 21 2011 756 762
3. S.A. Cannistra Cancer of the ovary N. Engl. J. Med. 351 2004 2519 2529
4. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen, and et al. A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 2011 2484 2496
5. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, H. Huang, and et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N. Engl. J. Med. 365 2011 2473 2483
6. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, and et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N. Engl. J. Med. 366 2012 1382 1392
7. C.N. Sternberg, I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, J. Wagstaff, and et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J. Clin. Oncol. 28 2010 1061 1068
8. A. du Bois, A. Floquet, J.W. Kim, J. Rau, J.M. Del Campo, M. Friedlander, and et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer J. Clin. Oncol. 32 2014 3374 3382
9. K. Alsop, S. Fereday, C. Meldrum, A. deFazio, C. Emmanuel, J. George, and et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J. Clin. Oncol. 30 2012 2654 2663
10. K.L. Bolton, G. Chenevix-Trench, C. Goh, S. Sadetzki, S.J. Ramus, B.Y. Karlan, and et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JAMA 307 2012 382 390
11. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, and et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol. 15 2014 852 861
12. A.R. Venkitaraman Cancer suppression by the chromosome custodians, BRCA1 and BRCA2 Science 343 2014 1470 1475
13. D.M. Hyman, and D.R. Spriggs Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer JAMA 307 2012 408 410
14. P.M. Vencken, M. Kriege, D. Hoogwerf, S. Beugelink, M.E. van der Burg, M.J. Hooning, and et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients Ann. Oncol. 22 2011 1346 1352
15. R.J. Motzer, T. Johnson, T.K. Choueiri, K.C. Deen, Z. Xue, L.N. Pandite, and et al. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms Ann. Oncol. 24 2013 2927 2928
16. C.F. Xu, N.X. Bing, H.A. Ball, D. Rajagopalan, C.N. Sternberg, T.E. Hutson, and et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes J. Clin. Oncol. 29 2011 2557 2564
17. B. Howie, C. Fuchsberger, M. Stephens, J. Marchini, and G.R. Abecasis Fast and accurate genotype imputation in genome-wide association studies through pre-phasing Nat. Genet. 44 2012 955 959
18. 1000 Genomes Project Consortium, G.R. Abecasis, A. Auton, L.D. Brooks, M.A. DePristo, R.M. Durbin, and et al. An integrated map of genetic variation from 1,092 human genomes Nature 491 2012 56 65
19. B.I. Rini, D.P. Cohen, D.R. Lu, I. Chen, S. Hariharan, M.E. Gore, and et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J. Natl. Cancer Inst. 103 2011 763 773
20. A.L. Price, N.J. Patterson, R.M. Plenge, M.E. Weinblatt, N.A. Shadick, and D. Reich Principal components analysis corrects for stratification in genome-wide association studies Nat. Genet. 38 2006 904 909
21. B. Devlin, and K. Roeder Genomic control for association studies Biometrics 55 1999 997 1004
22. J.-W. Kim, L.-Y. Wu, S. Mahner, T. Shoji, B.-G. Kim, J.-Q. Zhu, and et al. Pazopanib maintenance therapy in East Asian (EA) women with advanced epithelial ovarian cancer (AEOC): results of two clinical trials Presented at the Asian Society of Gynecologic Oncology Conference (ASGO); Kyoto, Japan December 12-14, 2013 (abstr WS1-07)
23. G. Rigakos, and E. Razis BRCAness: finding the Achilles heel in ovarian cancer Oncologist 17 2012 956 962
24. T. Pal, J. Permuth-Wey, J.A. Betts, J.P. Krischer, J. Fiorica, H. Arango, and et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2005 2807 2816
25. P. Harter, A. du Bois, C. Schade-Brittinger, A. Burges, K. Wollschlaeger, M. Gropp, and et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background Ann. Oncol. 16 2005 1801 1805
26. C.F. Xu, B.H. Reck, Z. Xue, L. Huang, K.L. Baker, M. Chen, and et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism Br. J. Cancer 102 2010 1371 1377
27. S. Zhang, R. Royer, S. Li, J.R. McLaughlin, B. Rosen, H.A. Risch, and et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer Gynecol. Oncol. 121 2011 353 357
28. F.J. Couch, K.L. Nathanson, and K. Offit Two decades after BRCA: setting paradigms in personalized cancer care and prevention Science 343 2014 1466 1470
29. G.C. Stuart, H. Kitchener, M. Bacon, A. duBois, M. Friedlander, J. Ledermann, and et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fFourth Ovarian Cancer Consensus Conference Int. J. Gynecol. Cancer 21 2011 750 755